TY - JOUR
T1 - Sequential combination of tamoxifen and high dose medroxyprogesterone acetate
T2 - Therapeutic and endocrine effects in postmenopausal advanced breast cancer patients
AU - Gasparini, Giampietro
AU - Canobbio, Luciano
AU - Galligioni, Enzo
AU - Fassio, Tiziana
AU - Brema, Fulvio
AU - Crivellari, Diana
AU - Villalta, Danilo
AU - Di Fronzo, Giovanni
AU - Talamini, Renato
AU - Monfardini, Silvio
PY - 1987
Y1 - 1987
N2 - A sequential combination of tamoxifen and medroxyprogesterone acetate has been evaluated in 42 postmenopausal untreated patients with metastatic breast cancer. Patients received tamoxifen 10 mg b.i.d., days 1-14, followed by medroxyprogesterone acetate 500 mg b.i.d., days 15-28, orally in an alternating sequence until progression. Twenty-two out of 40 evaluable patients showed an objective response to treatment (55%, 95% confidence limits 38-75%). A significantly higher response rate was observed in patients with age ≥ 70 years, with soft tissue dominant lesions and with only one metastatic site. Median time to progression was 41 weeks and the median survival time 88 weeks. In 4 cases treatment was discontinued because of severe toxicity while in the remaining patients no toxicity (20 patients) or mild side effects (17 patients) have been observed. After 2 months of therapy, this combination showed a progestogenic effect on the endocrine parameters inducing a significant decrease of SHBG, gonadotropins, testosterone and cortisol. These preliminary clinical results and the moderate toxicity of the sequential combination support the need to further investigate this approach.
AB - A sequential combination of tamoxifen and medroxyprogesterone acetate has been evaluated in 42 postmenopausal untreated patients with metastatic breast cancer. Patients received tamoxifen 10 mg b.i.d., days 1-14, followed by medroxyprogesterone acetate 500 mg b.i.d., days 15-28, orally in an alternating sequence until progression. Twenty-two out of 40 evaluable patients showed an objective response to treatment (55%, 95% confidence limits 38-75%). A significantly higher response rate was observed in patients with age ≥ 70 years, with soft tissue dominant lesions and with only one metastatic site. Median time to progression was 41 weeks and the median survival time 88 weeks. In 4 cases treatment was discontinued because of severe toxicity while in the remaining patients no toxicity (20 patients) or mild side effects (17 patients) have been observed. After 2 months of therapy, this combination showed a progestogenic effect on the endocrine parameters inducing a significant decrease of SHBG, gonadotropins, testosterone and cortisol. These preliminary clinical results and the moderate toxicity of the sequential combination support the need to further investigate this approach.
UR - http://www.scopus.com/inward/record.url?scp=0023429170&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023429170&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(87)90086-1
DO - 10.1016/0277-5379(87)90086-1
M3 - Article
C2 - 2960532
AN - SCOPUS:0023429170
VL - 23
SP - 1451
EP - 1459
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 10
ER -